Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Oral Lipid Nanocrystal Amphotericin B for Cryptococcal Meningitis: A Randomized Clinical Trial

Clinical Infectious Diseases(2023)10.1093/cid/ciad440Source: DataRank Database

Oral Lipid Nanocrystal Amphotericin B for Cryptococcal Meningitis: A Randomized Clinical Trial is a research paper published in Clinical Infectious Diseases (2023). On theSindex it has a DataRank of 1.3. It has been cited 65 times, with 41 citing works in its 1-hop citation network.

N/A

1.3DataRank · unranked

Scored on demand from live citation data

Deposits data Open Access65 citations · 41 citing works in its network

Download PDF

Cite:

Linked data & code

nct

Data availability

Repositories this paper deposited data in (declared in PubMed).

ClinicalTrials.govNCT04031833

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (17 grants)Impact (FWCI 11.20)OA: hybridTopics (42)IDs (PubMed, PMC, OpenAlex)Annotations (1)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

DataRank Breakdown

Base Score 48%Citation Network 52%

Base Score Contribution

0.628

From this paper's citation signal

Citation Network Contribution

0.681

From 29 citing papers with measurable signal

Learn more about DataRank methodology →

Top 5 citers driving the network score

Ranked by each citer's contribution to N(p) — log1p(C_q) divided by its reference count — out of 41 citers.

Oral Lipid Nanocrystal Amphotericin B (MAT2203) for the Treatment of Invasive Fungal Infections
Open Forum Infectious Diseases202412 citations15 referencesContributes 0.171
New treatment options for critically important WHO fungal priority pathogens
Clinical Microbiology and Infection202474 citations59 referencesContributes 0.073
Antifungal Therapies for Aspergillus spp.: Present and Future
Seminars in Respiratory and Critical Care Medicine20239 citations43 referencesContributes 0.054
Invasive fungal disease and antifungal prophylaxis in children with acute leukaemia: a multicentre retrospective Australian cohort study
The Lancet Regional Health - Western Pacific20249 citations52 referencesContributes 0.044
An update on newer antifungals
Expert Review of Anti-infective Therapy20257 citations59 referencesContributes 0.035

Authors (29)

Mucunguzi Atukunda ORCID,Enock Kagimu ORCID,Abdu K Musubire ORCID,Andrew Akampurira,Lillian Tugume ORCID

Live enrichment

PubMed:37606364 PMC:PMC10724459 OpenAlex:https://openalex.org/W4386046260

NIH

Grant: R01NS086312)

Matinas BioPharma

Grant: AI001123

Matinas BioPharma

Grant: AI001124)

NINDS NIH HHS

Grant: R01 NS110519

FIC NIH HHS

Grant: D43 TW009345

NCATS NIH HHS

Grant: KL2 TR002492

NCATS NIH HHS

Grant: UL1 TR002494

Intramural NIH HHS

Grant: ZIA AI001124

NIAID NIH HHS

Grant: T32 AI055433

Intramural NIH HHS

Grant: ZIA AI001123

NINDS NIH HHS

Grant: K23 NS122601

NINDS NIH HHS

Grant: R01 NS086312

National Institutes of Health

Grant: 1KL2TR002492-01

Institutional Career Development Core

National Institutes of Health

Grant: 5T32AI055433-08

Infectious Disease Training in Clinical Investigation

National Institutes of Health

Grant: 2R01NS086312-11

Improving Diagnostics and Neurocognitive Outcomes in HIV/AIDS-related Meningitis

National Institutes of Health

Grant: 3D43TW009345-14S1

Northern Pacific Global Health Leadership, Education, and Development for Early-career Researchers (NPGH LEADERs)

National Institutes of Health

Grant: 3UL1TR002494-02S1

University of Minnesota Clinical and TranslationalmScience Institute (UMN CTSI)

FWCI

11.20

Citation Percentile

1.0%

Citation Trend

2023

2024

2025

2026

hybridLicense: cc-by

journalhttps://academic.oup.com/cid/advance-article-pdf/doi/10.1093/cid/ciad440/51204212/ciad440.pdf

publisherhttps://academic.oup.com/cid/advance-article-pdf/doi/10.1093/cid/ciad440/51204212/ciad440.pdf

publisherhttps://academic.oup.com/cid/article-pdf/77/12/1659/54532192/ciad440.pdf

journalhttps://doi.org/10.1093/cid/ciad440

repositoryhttps://pubmed.ncbi.nlm.nih.gov/37606364

Fields of Study

Fungal Infections and StudiesAntifungal resistance and susceptibilityNail Diseases and TreatmentsHumansMeningitis, CryptococcalAmphotericin BFlucytosineDrug Therapy, CombinationAntifungal AgentsFluconazoleVaccinesLipids

MeSH Terms

Amphotericin BAntifungal AgentsDrug Therapy, CombinationFlucytosineHumansLipidsVaccinesFluconazoleMeningitis, Cryptococcal

Keywords

Amphotericin BFlucytosineMedicineTolerabilityInternal medicineGastroenterologyRandomized controlled trialPharmacologyAdverse effectAntifungalDermatologyHIVCryptococcal MeningitisAids-related Opportunistic InfectionVaccinesAntifungal AgentsHumansDrug Therapy, CombinationMeningitis, CryptococcalFluconazoleLipids

Sustainable Development Goals

SDG 0: Good health and well-being